CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Sanford C. Bernstein upped their price target on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $68.06.

CRISPR Therapeutics Stock Up 3.6%

Shares of CRSP stock opened at $53.52 on Friday. CRISPR Therapeutics has a 1 year low of $44.12 and a 1 year high of $78.48. The stock has a market cap of $5.17 billion, a PE ratio of -11.24 and a beta of 1.74. The business’s fifty day moving average is $52.37 and its 200-day moving average is $52.31. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.96 and a current ratio of 17.85.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The firm had revenue of $10.18 million during the quarter. Equities analysts expect that CRISPR Therapeutics will post -4.53 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. GSK plc acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at about $168,890,000. Orbis Allan Gray Ltd increased its holdings in CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after buying an additional 1,201,600 shares during the last quarter. State Street Corp raised its position in CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after acquiring an additional 859,334 shares in the last quarter. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock valued at $551,777,000 after acquiring an additional 735,084 shares during the last quarter. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $25,706,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: HC Wainwright remains bullish: The firm maintained a “Buy” rating and an $80 price target, while modestly narrowing its projected losses for fiscal 2026, fiscal 2027 and fourth-quarter 2027. The revisions suggest slightly better expected profitability, although CRISPR is still forecast to remain unprofitable. HC Wainwright CRISPR Therapeutics estimates
• Positive Sentiment: Other bullish coverage supports sentiment: Piper Sandler reaffirmed its “Buy” rating on CRISPR Therapeutics, while Brookline Capital Markets raised its fiscal 2027 EPS forecast to a loss of $4.51 from a loss of $5.05. Piper Sandler reaffirms Buy rating
• Neutral Sentiment: Wells Fargo issued a Hold rating: The rating indicates a more cautious view and may limit the impact of the bullish recommendations, particularly with CRSP still reporting substantial losses. Wells Fargo Hold rating
• Negative Sentiment: Brookline lowered its fiscal 2026 outlook: The firm increased its projected fiscal 2026 loss to $5.63 per share from $5.36 and reduced its fourth-quarter 2026 forecast to a $1.87-per-share loss from $1.69. These revisions highlight near-term earnings pressure.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.